Navigation Links
Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Date:8/27/2013

e Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non‐clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; Orexigen's ability to enter into a collaborative partnership for Contrave outside North America on acceptable terms, if at all; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Annual Report on Form 10‐K filed with the Securities and Exchange Commission March 14, 2013 and its other reports, which are available from the SEC's website (www.sec.gov) and on Orexigen's website (www.orexigen.com) under the heading "Investor Relations." All forward‐looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

 Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... -- The president of Cars.com and one ... and other Internet topics in the Sept. 29 inaugural speaker ... , ,The speaker, Mitch Golub, has an extensive background in ... joined Classified Ventures, which includes Cars.com, after a 21-year career ...
... Madison, Wis. - An improved warning system could ... representatives of a Madison company involved in emergency communications. ... the levees were breached, where people could have been ... said Kendall Post, chief technology officer of Madison-based ...
... Inc., has launched interactive, personalized services for Milwaukee ... the company announced Thursday. Traffic.com will provide area ... displays of roadway traffic conditions including congestion levels, ... in a news release. , ,Data for the ...
Cached Biology Technology:Cars.com president slated for Milwaukee event 2Madison company urges disaster warning upgrades 2
(Date:4/23/2014)... signing ceremony in Buenos Aires yesterday, Argentina joins ... associate member state. The move strengthens the ties ... communities. It grants Argentinian scientists access to EMBL,s ... collaborations. , "Ever since its inception, fostering excellent ... been at the core of EMBL,s mission," says ...
(Date:4/23/2014)... of the family of bacteria that causes whooping ... reveals surprising findings about the bacteria,s origin and ... strategies to control this respiratory disease, which kills ... of 343 strains of the Bordetella pertussis ... the last 100 years illustrates how vaccination has ...
(Date:4/23/2014)... social mammals, ravens form different types of social relationships ... they also form strict dominance relations. From a cognitive ... key ability in daily social life ("knowing who is ... members have with each other sets the stage for ... of this study have been published in the scientific ...
Breaking Biology News(10 mins):Impact of whooping cough vaccination revealed 2Ravens understand the relations among others 2
... (OTC,Bulletin Board: CICI) -- Communication Intelligence Corporation ("CIC" ... solutions for,the financial industry and the recognized leader ... for the fourth quarter,and the year ended December ... ended December 31, 2007 increased 63% to,$800,000, compared ...
... article entitled Passage Times for Polymer Translocation Pulled ... 5, of the Biophysical Journal, which is available online. ... Pulled through a Narrow Pore When polymeric ... a process known as translocation, they leave a distinct ...
... The growth in China,s carbon dioxide (CO2) emissions is ... atmospheric greenhouse gases even more difficult, according to a ... Berkeley, and UC San Diego. Previous estimates, including ... say the region that includes China will see a ...
Cached Biology News:Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 2Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 3Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 4Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 5Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 6Media highlights for February in Biophysical Journal 2Alarming growth in expected CO2 emissions in China, finds UC analysis 2Alarming growth in expected CO2 emissions in China, finds UC analysis 3
...
... with the xPONENT Software Interface is ... assays using Upstate's Beadlyte® reagents. This ... friendly xPONENT software developed by Luminex. ... for commercial or home-made multiplex kits. ...
... turntable. Provides up to 30 minutes of walkaway time. Automatic Calibration. Five minute ... RS-232 port. ... ... ...
Vybrant® Multidrug Resistance Assay Kit...
Biology Products: